Figure 5

Combination effects of YM155 and cancer chemotherapeutics on breast cancer cell viability. MCF-7 cells were treated with YM155 (dose range 0.0004 to 0.100 μmol/L), in combination with either doxorubicin (Doxo), taxol, camptothecin (CPT), or etoposide (ETOP, dose range per each agent, 0.004 to 1 μmol/L) as a 7 × 7 matrix of concentrations in a cell viability assay. The excess over BLISS independence (left) and percentage of growth inhibition (right) are shown as a concentration range for each drug combination.